Translational Research

This line of research is at the heart of the Nordic EMBL Partnership for Molecular Medicine. Also, the key challenge of Finnish biomedical sciences is the translation of innovations to the industry and to the clinic. This gap between basic and clinical/industrial research is widening globally and major efforts to build translational research centres have been started in the EU and USA to bridge basic and clinical research. FIMM plans to develop towards a translational centre with both diagnostics and drug discovery activities.

There are particular strengths and promises in the following areas:

genetic risk factors for disease
biomarkers from serum and tissues for diagnosis of cancer
drugging key cancer pathways

Together, these capabilities formulate a strong base for personalized medicine research, i.e. matching the right patients for the right therapies. This is key towards improving efficacy and costs of health care and delivering the best treatment for each patient.

Scientific Highlights

GeneSapiens - a catalogue of expression of all human genes (23.06.2009)
Population cohort study finds six genetic variants associated with 'bad' cholesterol (in Finnish) (27.04.2009)
Suomalaiset väestöaineistot ja uudet perimän analyysimenetelmät paljastavat kansantautien syitä kolmessa laajassa tutkimuksessa
All news articles

News

Academician of Science Leena Palotie is portrayed on a new postage stamp issued today on the International Women´s Day, 8th March, 2010 (08.03.2010)
FIMM Launch Event 16-17 March 2010 (05.02.2010)
Finland invests €1.85 million in pan-European infrastructure for biomedical research (03.02.2010)
Finland has made its first specific commitment to the development of European biomedical research infrastructures (BMS ESFRIs) by supporting a joint pilot infrastructure project in bioinformatics (ELIXIR), biobanking (BBMRI) and translational research (EATRIS). The initial commitment of 1.85 M€ is to support preparation and pilot studies in 2010.
All news articles